drugset / Trial / NCT00817271

To Evaluate the Response to Glucagon During Hypoglycemia

NCT00817271

Phase 1 Completed 8 enrolled AstraZeneca
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the response to Glucagon versus the spontaneous hormonal response to low blood sugar levels in T2DM Patients treated with AZD1656 and Metformin

Timeline

Start
2009-02
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1656 Small molecule Oral
Subject Glucagon Peptide 1 mg Other